0ACH Stock Chart & Stats
€26.50
-€1.10(-4.15%)
At close: 4:00 PM EDT
€26.50
-€1.10(-4.15%)
Day’s Range― - ―
52-Week Range€16.81 - €39.38
Previous CloseN/A
Volume7.32K
Average Volume (3M)27.35K
Market Cap
€876.16M
Enterprise Value€731.65
Total Cash (Recent Filing)€84.82M
Total Debt (Recent Filing)€57.41M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Dec 08, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding35,912,260
10 Day Avg. Volume5,762
30 Day Avg. Volume27,349
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)264.15
Price to Sales (P/S)41.46
P/FCF Ratio-30.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.00Price Target Upside43.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€47.41M
Bulls Say, Bears Say
Bulls Say
UZEDY Royalty GrowthRapid UZEDY sales growth is expanding MedinCell’s royalty stream and validating its long-acting injectable technology. Continued partner commercialization could provide increasingly recurring revenue and support a stronger financial base over the next several years.
Olanzapine LAI Regulatory ProgressRegulatory advancement materially reduces development uncertainty for a potential second major commercial product. If approved, olanzapine LAI could diversify royalty sources and create a faster revenue ramp, strengthening the platform’s long-term commercial profile.
Expanding Partnered PipelineA broad formulation pipeline and active partnerships increase the number of potential future milestones and royalties. Partner funding also helps validate BEPO technology while sharing development costs, improving the chance of building multiple durable revenue streams.
Bears Say
Persistent Losses And Cash BurnSustained losses and renewed cash consumption show that commercial royalties have not yet funded the company’s investment base. Continued cash burn increases dependence on liquidity, future partnerships or capital access before the pipeline reaches maturity.
Milestone-Dependent Revenue VolatilityRevenue remains exposed to the timing of one-off development milestones, making reported performance uneven even as royalty income grows. This variability can complicate planning and leaves the business reliant on successful program progression and partner decisions.
Partner And Regulatory Execution RiskMedinCell relies on partners for commercialization and on regulators for product approvals, limiting its direct control over timelines and outcomes. Delays or altered pathways could postpone royalties, increase development costs and weaken the expected pipeline ramp.
MedinCell SA News
0ACH FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest share price was €16.81 and its highest was €39.38 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is €876.16M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Dec 08, 2026 which is in 102 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Jun 16, 2026. The company reported -€0.45 earnings per share for the quarter, missing the consensus estimate of -€0.14 by -€0.31.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is -0.22.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 35,912,260 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.45 in its last earnings report, missing expectations of -€0.14. Following the earnings report the stock price went up 0.216%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in GB:0ACH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedinCell SA
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
0ACH Stock 12 Month Forecast
Average Price Target
€38.00
▲(43.40% Upside)